Triple-negative breast cancer (TNBC) is a type of breast cancer that does not have three receptors commonly used to guide treatment: estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). Because these receptors are absent, hormonal therapies and HER2-targeted treatments that are useful for some other breast cancers generally do not work against TNBC. Treatment therefore relies on other approaches, including chemotherapy, immunotherapy for selected patients, surgery, radiation therapy, and newer targeted treatments.
What Makes Triple-Negative Breast Cancer Different?
Breast cancer cells can carry receptors that respond to hormones or growth signals.
The three markers used to define TNBC are:
- Estrogen receptor (ER)
- Progesterone receptor (PR)
- HER2
In triple-negative breast cancer, testing shows that the tumor does not have significant levels of these three receptors.
This classification is important because receptor status influences treatment decisions.
Symptoms of Triple-Negative Breast Cancer
TNBC can cause the same symptoms as other forms of breast cancer.
Possible signs include:
- A new lump in the breast
- Thickening of breast tissue
- Changes in breast size or shape
- Skin dimpling
- Nipple inversion
- Nipple discharge
- Changes in breast skin
- Persistent breast swelling
- A lump or swelling in the underarm
A breast lump does not automatically mean cancer. Many breast changes are caused by benign conditions.
However, a new or persistent breast change should be evaluated by a healthcare professional.
How Triple-Negative Breast Cancer Is Diagnosed
Diagnosis typically involves several steps.
Mammography
A mammogram uses X-rays to create images of breast tissue.
It may identify a suspicious mass or other abnormality that requires additional evaluation.
Ultrasound
Breast ultrasound uses sound waves to create images of breast tissue.
It can help distinguish fluid-filled cysts from solid masses and can be particularly useful when evaluating a specific lump.
Breast MRI
Magnetic resonance imaging may be recommended in selected situations, particularly for people with certain risk factors or when additional information about the extent of disease is needed.
Biopsy
A biopsy is required to confirm breast cancer.
During a biopsy, tissue is removed from the suspicious area and examined by a pathologist.
Receptor Testing
After breast cancer is diagnosed, the tumor is tested for ER, PR, and HER2.
TNBC is identified when testing shows that the tumor is negative for all three.
Additional laboratory testing may provide information about other biomarkers that can influence treatment decisions.
Genetic Testing
Genetic testing can be particularly relevant for people diagnosed with TNBC.
Inherited changes in genes such as BRCA1 and BRCA2 can increase the risk of breast and ovarian cancers.
Genetic counseling and testing may be recommended based on age at diagnosis, family history, ancestry, tumor characteristics, and applicable clinical guidelines.
Identifying an inherited mutation can sometimes influence treatment decisions and may also provide useful information for relatives.
Stages of Triple-Negative Breast Cancer
TNBC can be classified from early-stage disease to metastatic disease.
Staging considers factors such as:
- Tumor size
- Lymph-node involvement
- Spread to other tissues
- Tumor characteristics
Early-stage TNBC is confined to the breast and possibly nearby lymph nodes.
Metastatic TNBC has spread to distant organs.
Common sites of metastatic breast cancer can include:
- Bone
- Liver
- Lungs
- Brain
The stage at diagnosis is one of the most important factors influencing treatment and prognosis.
Treatment for Early-Stage TNBC
Treatment for early-stage TNBC commonly involves a combination of therapies.
Depending on the specific case, treatment may include:
- Chemotherapy
- Immunotherapy
- Surgery
- Radiation therapy
- Targeted treatment for selected patients
Treatment is often coordinated by a multidisciplinary cancer team.
Neoadjuvant Chemotherapy
Neoadjuvant therapy is treatment given before surgery.
For TNBC, chemotherapy is frequently given before surgery because it can:
- Shrink the tumor
- Treat microscopic cancer cells throughout the body
- Provide information about how the cancer responds to treatment
- Potentially make surgery easier
For certain patients with early-stage TNBC, pembrolizumab may be combined with chemotherapy before surgery and continued after surgery.
The specific treatment depends on cancer stage, biomarker results, overall health, and treatment eligibility.
Immunotherapy
Immunotherapy has become an important part of treatment for some people with TNBC.
Pembrolizumab, an immune checkpoint inhibitor, is used in specific settings, particularly certain high-risk early-stage TNBC and advanced disease.
It works by blocking the PD-1 pathway, helping immune cells recognize and attack cancer cells.
Not every person with TNBC is eligible for immunotherapy.
Potential side effects can include immune-related inflammation affecting organs such as the thyroid, lungs, liver, intestines, or skin.
Surgery
Surgery is often an important component of treatment for localized TNBC.
Two broad surgical approaches include:
Lumpectomy
A lumpectomy removes the tumor and a surrounding margin of healthy tissue while preserving most of the breast.
Radiation therapy is commonly recommended after breast-conserving surgery.
Mastectomy
A mastectomy removes most or all breast tissue.
The choice between lumpectomy and mastectomy depends on tumor characteristics, breast anatomy, genetic factors, patient preferences, and other clinical considerations.
Lymph Node Surgery
Doctors may evaluate nearby lymph nodes to determine whether cancer has spread beyond the breast.
A sentinel lymph node biopsy is commonly used in appropriate patients.
If cancer is found in lymph nodes, additional treatment decisions may be influenced by the extent of lymph-node involvement.
Radiation Therapy
Radiation uses high-energy radiation to destroy remaining cancer cells.
It may be recommended after breast-conserving surgery and in selected patients following mastectomy.
Radiation decisions depend on tumor size, lymph-node involvement, surgical findings, and other risk factors.
PARP Inhibitors
People with inherited BRCA mutations and certain high-risk breast cancers may be eligible for PARP inhibitor treatment.
Olaparib is an example of a PARP inhibitor used in selected patients with HER2-negative breast cancer and inherited BRCA mutations.
PARP inhibitors interfere with cancer cells' ability to repair certain types of DNA damage.
Eligibility depends on genetic testing, cancer stage, previous treatment, and other clinical factors.
Antibody-Drug Conjugates
Antibody-drug conjugates combine an antibody that recognizes a cancer-related target with a chemotherapy drug.
Sacituzumab govitecan is an antibody-drug conjugate used for certain patients with advanced or metastatic TNBC after previous treatments.
Other antibody-drug conjugates and targeted therapies continue to be studied as treatment approaches for breast cancer.
Treatment for Metastatic TNBC
Metastatic TNBC cannot currently be considered curable in most cases, but treatment can control the disease, relieve symptoms, and extend survival.
Treatment selection can depend on:
- PD-L1 status
- BRCA mutation status
- Previous therapies
- Tumor characteristics
- Overall health
- Previous treatment response
Possible treatments include:
- Chemotherapy
- Immunotherapy
- Antibody-drug conjugates
- PARP inhibitors for selected patients
- Clinical trials
PD-L1 Testing
PD-L1 is a protein that can influence whether immunotherapy may be useful.
In certain metastatic TNBC settings, PD-L1 testing can help identify people who may benefit from an immune checkpoint inhibitor combined with chemotherapy.
The exact test and threshold depend on the treatment being considered.
Why Clinical Trials Matter
TNBC remains an active area of cancer research.
Clinical trials are evaluating:
- New immunotherapies
- Targeted therapies
- Antibody-drug conjugates
- Combination treatments
- New approaches to prevent recurrence
- Personalized treatment strategies
Clinical trials may be appropriate at different stages of treatment, depending on eligibility.
Recurrence Risk
TNBC can have a higher risk of recurrence during the first few years after diagnosis compared with some hormone receptor-positive breast cancers.
Recurrence can occur:
- In the breast
- In nearby lymph nodes
- In the chest area
- In distant organs
The risk varies considerably among individuals and depends on tumor stage, response to treatment, lymph-node involvement, tumor biology, and other factors.
Follow-Up Care
After treatment, ongoing follow-up is important.
Follow-up may include:
- Regular medical appointments
- Mammography when appropriate
- Monitoring for treatment side effects
- Management of other health conditions
- Discussion of new symptoms
Routine imaging for distant metastases is not necessarily performed in every person without symptoms.
Living With Triple-Negative Breast Cancer
Cancer treatment can affect physical and emotional well-being.
Potential concerns include:
- Fatigue
- Neuropathy
- Changes in appetite
- Sleep problems
- Anxiety
- Depression
- Changes in body image
- Menopausal symptoms
- Financial stress
Supportive care can address many of these issues while cancer treatment continues.
Nutrition and Physical Activity
There is no specific diet proven to cure TNBC.
A balanced eating pattern can support general health during and after treatment.
Depending on individual needs, this may include:
- Vegetables and fruits
- Whole grains
- Protein-rich foods
- Healthy fats
- Adequate fluids
Physical activity can also support strength, cardiovascular health, mood, and recovery when medically appropriate.
What About Supplements?
Supplements should not be assumed to prevent recurrence or improve cancer treatment.
Some supplements can interfere with medications or chemotherapy.
Before using vitamins, herbal products, antioxidants, or other supplements during cancer treatment, discussing them with the oncology team is important.
Prognosis
The outlook for TNBC depends on several factors.
These include:
- Stage at diagnosis
- Tumor size
- Lymph-node involvement
- Response to treatment
- Tumor biology
- Genetic factors
- Overall health
People diagnosed with early-stage TNBC can receive treatment with curative intent.
Treatment advances, including immunotherapy and targeted therapies, have expanded the available approaches for certain patients.
Final Thoughts
Triple-negative breast cancer is defined by the absence of estrogen receptors, progesterone receptors, and HER2. Because hormone therapy and HER2-targeted treatments are generally not effective against TNBC, treatment relies on approaches such as chemotherapy, immunotherapy, surgery, radiation, PARP inhibitors for selected patients, and newer targeted therapies.